BLRX BioLineRx Ltd
Company Analysis
Latest News
🔴 BioLineRx is trading 6.5% down today amid broader market pressure from hotter-than-expected inflation
BioLineRx is trading 6.51% lower at $2.01, with broader market weakness the likeliest available context, though no stock-specific cause is confirmed. - No new...
🟢 BioLineRx is trading 5% up in pre-market — no confirmed overnight catalyst
BioLineRx is trading 5.07% higher at $2.28 before the October 13, 2026 open, versus its October 12 close of $2.17; no confirmed overnight catalyst was...
🔴 BioLineRx is trading 5.4% down in pre-market
BioLineRx is trading 5.4% down at $2.12 before the October 12, 2026 market open; no clear company-specific announcement explaining the decline surfaced in...
🟢 BioLineRx is trading 6.8% up in pre-market
BioLineRx is trading at $2.36, up 6.79% before the October 8, 2026, market open; the reason for the move remains unclear. - No clear company-specific...
🔴 BioLineRx is trading 6.4% down amid broader biotech weakness and risk-off pressure
BioLineRx is trading 6.38% down at $2.19 on October 7, 2026, consistent with broader biotech weakness and risk-off pressure rather than a confirmed...
🟢 BioLineRx is trading 7% up in pre-market with no new company-specific announcement found
BioLineRx is trading $2.51, up 6.81%, with no new company-specific announcement found to explain the October 1 pre-market rise. - BioLineRx’s...
🔴 BioLineRx is trading 6% down in after-hours trading
BioLineRx is trading 5.96% lower at $2.21 after hours, extending a weak stretch without a clear company-specific catalyst. - Shares closed at $2.35 in the...
🔴 BioLineRx is trading 5.8% down amid broader market weakness
BioLineRx is trading at $2.44, down 5.79%, in a risk-off session amid geopolitical tensions and rising oil prices; broader market weakness may contribute but...
🟢 BioLineRx is trading 6.28% up today; catalyst remains uncertain
BioLineRx is trading at $2.57, up +6.28%, with the catalyst uncertain. - No clear company-specific announcement was identified for September 23, 2026. - The...
🟢 BioLineRx is trading 5.37% up in pre-market amid a 2.61% biotech pre-market gain
BioLineRx is trading at $2.55, up 5.37%, with the broader biotech sector’s 2.61% pre-market gain the strongest available explanation for the move. - No clear...
🟢 BioLineRx is trading 9.8% up in pre-market
BioLineRx is trading +9.80% at $2.80 after no clear company-specific catalyst was identified for September 10, 2026. - The latest available company update...
🔴 BioLineRx is trading 9.02% down in after-hours trading with no new company-specific catalyst identified
BioLineRx is trading 9.02% down at $2.32 after-hours on September 9, 2026, versus the regular-session close of $2.55; no major company announcement, earnings...
🔴 BioLineRx is trading 5.98% down in after-hours trading after Q2 net loss widened
BioLineRx is trading 5.98% down now at $2.51 after investors continued digesting its August 31, 2026, second-quarter results. - Revenue was $0.3 million,...
🔴 BioLineRx is trading 8.76% down in pre-market after Q2 revenue missed expectations and losses widened
BioLineRx is trading 8.76% down in pre-market at $2.50 as investors continue digesting its August 31, 2026 second-quarter results, which showed revenue below...
🔴 BioLineRx is trading 6.88% down today after weak Q2 results and dilution pressure
BioLineRx is trading 6.88% down at $2.57 after weak Q2 financial results and financing-related dilution pressure. - August 31 earnings showed Q2 royalty...
🔴 BioLineRx is trading 6.81% down in after-hours trading after Q2 revenue missed expectations
BioLineRx is trading at $2.57 (-6.81%) in after-hours trading after second-quarter revenue missed expectations and APHEXDA royalty income remained weak. • The...
🔴 BioLineRx is trading 6.5% down today as biotech falls 4.24%
BioLineRx is trading 6.5% down at $2.62 amid broad risk-off selling, with biotech down 4.24% and the Nasdaq down 1.00%. - September 1, 2026 weakness followed...
🔴 BioLineRx is trading 6.79% down in pre-market after second-quarter revenue missed estimates
BioLineRx is trading 6.79% down in pre-market at $2.61 after second-quarter revenue of $0.3 million missed the $0.5 million analyst estimate. - In its August...
🟢 BioLineRx is trading 11.44% up today amid GLIX1 clinical expansion
BioLineRx is trading at $2.85 (+11.44%), with investors possibly responding to GLIX1’s clinical expansion. - Reported $0.3 million in second-quarter revenue,...
🟢 BioLineRx is trading 5.65% up today after accelerated GLIX1 development
BioLineRx is trading at $2.70 (+5.65%) after its August 31, 2026 earnings release, as GLIX1 progress and financing may be outweighing weaker royalty...